NLS Pharmaceutics Ltd

NEW
NAS:NLSP (Switzerland)   Ordinary Shares
$ 1.91 -0.05 (-2.55%) 11:08 PM EST
At Loss
Volume:
89.31K
Avg Vol (2M):
485.85K
Trade In:
Volume:
89.31K
At Loss
Avg Vol (2M):
485.85K

Business Description

NLS Pharmaceutics Ltd
NAICS : 325199
ISIN : CH1384053976

Share Class Description:

NLSP: Ordinary Shares
Description
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
Name Current Vs Industry Vs History
Cash-To-Debt 0.32
Equity-to-Asset -7.77
Debt-to-Equity -0.19
Debt-to-EBITDA -0.27
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.15
Quick Ratio 0.15
Cash Ratio 0.07

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -40.2
Shareholder Yield % -30.5
Name Current Vs Industry Vs History
ROA % -372.6
ROIC % -557.34
3-Year ROIIC % 842.91
ROC (Joel Greenblatt) % -95445

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -0.89
EV-to-EBITDA -0.89
EV-to-Forward-Revenue 64.6
EV-to-FCF -1.45
Earnings Yield (Greenblatt) % -112.36
FCF Yield % -86.6

Financials (Next Earnings Date:2025-01-10 Est.)

NLSP's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:NLSP

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

NLS Pharmaceutics Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -6.74
Beta -0.62
3-Year Sharpe Ratio -0.56
3-Year Sortino Ratio -0.77
Volatility % 104
14-Day RSI 23.76
14-Day ATR ($) 0.383988
20-Day SMA ($) 2.81225
12-1 Month Momentum % -79.41
52-Week Range ($) 1.75 - 24.336
Shares Outstanding (Mil) 2.37

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

NLS Pharmaceutics Ltd Filings

Filing Date Document Date Form
No Filing Data

NLS Pharmaceutics Ltd Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

NLS Pharmaceutics Ltd Frequently Asked Questions

What is NLS Pharmaceutics Ltd(NLSP)'s stock price today?
The current price of NLSP is $1.91. The 52 week high of NLSP is $24.34 and 52 week low is $1.75.
When is next earnings date of NLS Pharmaceutics Ltd(NLSP)?
The next earnings date of NLS Pharmaceutics Ltd(NLSP) is 2025-01-10 Est..
Does NLS Pharmaceutics Ltd(NLSP) pay dividends? If so, how much?
NLS Pharmaceutics Ltd(NLSP) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1